Abstracts tagged "Mouse"

Abstract Number: 0737 • ACR Convergence 2023
Unraveling Pathophysiology and Hematopoiesis of VEXAS Syndrome by Multi-omics Analysis and Targeted Gene Editing
Corrado Campochiaro¹, Raffaella Molteni², Martina Fiumara³, Alessandro Tomelleri⁴, Elisa Diral⁵, Davide Stefanoni², Angelica Varesi³, Alessandra Weber³, Roberta Alfieri⁶, Luisa Albano³, Maddalena Panigada², Eleonora Cantoni², Daniele Canarutto³, Luca Basso-Ricci³, Pamela Quaranta³, Angelo D’Alessandro⁷, marco Matucci Cerinic⁸, Raffaella Di Micco³, Serena Scala³, Alessandro Aiuti³, Fabio Ciceri⁵, Ivan Merelli³, Lorenzo Dagna⁹, Simone Cenci², Luigi Naldini³, Samuele Ferrari³ and Giulio Cavalli², ¹IRCCS San Raffaele Hospital, Unit of Immunology, Rheumatology, Allergy and Rare Disease. Vita-Salute San Raffaele University, Milan, Italy, ²Division of Genetics and Cell Biology, IRCCS San Raffaele Scientific Institute, Milan, Italy, ³San Raffaele Telethon Institute for Gene Therapy, IRCCS San Raffaele Scientific Institute, Milan, Italy, ⁴Unit of Immunology, Rheumatology, Allergy and Rare Diseases, San Raffaele Scientific Institute, Milano, Italy, ⁵Unit of Haematology and Bone Marrow Transplantation, IRCCS San Raffaele Hospital, Milan, Italy, ⁶Institute for Biomedical Technologies, National Research Council, Segrate, Italy, ⁷Department of Biochemistry and Molecular Genetics, University of Colorado Denver - Anschutz Medical Campus, Aurora, CO, ⁸Unit of Immunology, Rheumatology, Allergy and Rare diseases, IRCCS San Raffaele Hospital, Milan, Milan, Italy, ⁹Department of Internal Medicine, IRCCS San Raffaele Hospital and Vita-Salute San Raffaele University, Milan, Italy
Background/Purpose: VEXAS syndrome is an adult-onset, X-linked, life-threatening, autoinflammatory and hematological disease caused by somatic mutation in UBA1 gene. To understand its pathophysiology, we aimed…
Abstract Number: 0879 • ACR Convergence 2023
Recommendations for a Standardized Approach to Histopathologic Evaluation of Synovial Membrane in Murine Models of Experimental Osteoarthritis
Alia Obeidat¹, Sung Yeon Kim², Baofeng Hu³, Jun Li¹, Shingo Ishihara¹, Rui Xiao⁴, Rachel Miller¹, Anne-Marie Malfait¹ and Carla Scanzello⁵, ¹Rush University Medical Center, Chicago, IL, ²University of Pennsylvania School of Engineering and Applied Sciences, Philadelphia, PA, ³University of Pennsylvania, Wynnewood, PA, ⁴Department of Biostatistics, Epidemiology and Informatics, Perelman School of Medicine, University of Pennsylvania,Department of Pediatrics Division of Biostatistics, Children's Hospital of Philadelphia, Philadelphia, PA, ⁵Translational Musculoskeletal Research Center, Corp. Michael J Crescenz VA Medical Center,4Division of Rheumatology, Perelman School of Medicine University of Pennsylvania, Philadelphia, PA
Background/Purpose: Synovial pathology is an active component of osteoarthritis (OA) that has been linked to disease progression and pain in patients. Macroscopic and microscopic grading…
Abstract Number: 0895 • ACR Convergence 2023
Lipocalin-2 Promotes Cutaneous and Neuropsychiatric Disease in Murine Lupus
Chaim Putterman¹, Elise Mike² and Sayra Garcia¹, ¹Albert Einstein College of Medicine, Bronx, NY, ²Johns Hopkins, Bronx, NY
Background/Purpose: One central mechanism believed to contribute to the pathogenesis of neuropsychiatric systemic lupus erythematosus (NPSLE) is temporary disruption of the blood brain barrier (BBB).…
Abstract Number: 2544 • ACR Convergence 2023
Microbial Metabolism of Methotrexate Contributes to Its Pharmacokinetics in Vivo
Diego Orellana, Mohana Mukherjee, Moriah Sandy, Peter Turnbaugh and Renuka Nayak, University of California San Francisco, San Francisco, CA
Background/Purpose: Methotrexate (MTX) is a first-line treatment drug used in rheumatoid arthritis (RA) patients. However, only 30-40% of patients tolerate the drug and achieve adequate…
Abstract Number: 0057 • ACR Convergence 2023
GM-CSF receptor/SYK/JNK/FOXO1/CD11c Signaling Enhances Cell Migration to Promote Atherosclerosis
Daisuke Tsukui¹, Kimura Yoshitaka¹ and Hajime Kono², ¹Teikyo University School of Medicine, Itabashi-ku, Japan, ²Teikyo University School of Medicine, Tokyo, Japan
Background/Purpose: Atherosclerosis involves both dyslipidemia and chronic inflammatory disease; however, lipid-lowering agents do not completely eliminate the risks of cardiovascular events. In addition, chronic systemic…
Abstract Number: 0063 • ACR Convergence 2023
Investigating Macrophage Repopulation in the Synovium
Jessica Maciuch¹, Yidan Wang², Slim Fourati¹, Harris Perlman¹ and Deborah Winter³, ¹Northwestern University, Chicago, IL, ²Northwestern University, Hanover Park, IL, ³Northwestern University, Skokie, IL
Background/Purpose: Rheumatoid Arthritis (RA) is an autoimmune disease characterized by chronic inflammation of the joints. Macrophages are a key mediator of pro-inflammatory signaling, contributing to…
Abstract Number: 0601 • ACR Convergence 2023
Selective Disposition of Voclosporin, Cyclosporine, and Tacrolimus in Renal Tissue
Simon Zhou¹, Krishani Kumari Rajanayake², Miao He², Bo Wen², Ankhbayar Lkhagva², Ernie Yap³, Duxin Sun², Jennifer Cross¹, Kory Engelke¹ and Robert B. Huizinga⁴, ¹Aurinia Pharmaceuticals Inc., Rockford, MD, ²University of Michigan, Ann Arbor, MI, ³Aurinia Pharmaceuticals Inc., Edmonton, AB, Canada, ⁴Reformation Consulting Services, North Saanich, BC, Canada
Background/Purpose: The calcineurin inhibitors (CNI) cyclosporine (CSA) and tacrolimus (TAC) were revolutionary when first introduced for solid organ transplant. Voclosporin (VCS), a novel CNI, is…
Abstract Number: 0158 • ACR Convergence 2022
Effect of Type I IFN on Mitochondria and Muscle Weakness in Myositis
Melissa Morales, Joanna Parkes, Sabrina Narvesen and Rita Spathis, Department of Pharmaceutical Sciences, Binghamton University, Binghamton, NY
Background/Purpose: Muscle weakness is a hallmark of autoimmune myositis. The mechanisms that contribute to muscle weakness are currently unknown. The observed ineffectiveness after immunomodulatory treatment…
Abstract Number: 0341 • ACR Convergence 2022
Clinical Applications of Urine SERPINC1/ORM1 in MRL-lpr Lupus Nephritis-Prone Mice
YoungEun Kim¹, Eun-Ju Lee¹, Soo Min Ahn¹, Ji Seon Oh², Seokchan Hong¹, Chang Keun Lee¹, Bin Yoo¹ and Yong Gil Kim¹, ¹Department of Rheumatology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea, Seoul, Republic of Korea, ²Department of Information Medicine, Big Data Research Center, Asan Medical Center, Seoul, Republic of Korea
Background/Purpose: Despite improvements in the treatment of lupus nephritis (LN), the prognosis remains unsatisfactory, and a need for non-invasive biomarkers for early detection endures. Previously,…
Abstract Number: 0588 • ACR Convergence 2022
S-nitrosoglutathione Reductase (GSNOR) Regulates Osteoclast Differentiation
Toshihiro Tanioka¹, Kohei Maeda¹, Rei Takahashi¹ and Takeo Isozaki², ¹Division of Pathogenesis and Translational Medicine, Department of Clinical Pharmacy, Showa University School of Pharmacy, Tokyo, Japan, ²Division of Rheumatology, Department of Medicine, Showa University School of Medicine, Tokyo, Japan
Background/Purpose: S-nitrosoglutathione (GSNO) reductase (GSNOR) is an enzyme which decomposes GSNO and downregulates protein S-nitrosylation. It has been reported that GSNOR KO mice have enhanced…
Abstract Number: 1032 • ACR Convergence 2022
Anti-arthritogenic Effect of Smoking in Curdlan-Administered SKG Mice
YoungEun Kim¹, Eun-Ju Lee¹, Jae-Hyun Lee¹, Soo Min Ahn¹, Ji Seon Oh², Seokchan Hong¹, Chang Keun Lee¹, Bin Yoo¹ and Yong Gil Kim¹, ¹Department of Rheumatology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea, Seoul, Republic of Korea, ²Department of Information Medicine, Big Data Research Center, Asan Medical Center, Seoul, Republic of Korea
Background/Purpose: Alpha7 nicotinic acetylcholine receptor (α7nAChR), a member of AChR expressed in various immune cells and synoviocytes, has an important role in the anti-inflammatory pathway…
Abstract Number: 2265 • ACR Convergence 2022
Autoimmune RNA Dysregulation and Seizures: Therapeutic Prospects in Neuropsychiatric Systemic Lupus Erythematosus
Henri Tiedge¹, ILHAM MUSLIMOV², Valerio Berardi², Stacy Stephenson³, Ellen M. Ginzler⁴, Anca Askanase⁵ and John Hanly⁶, ¹SUNY, Downstate Medical Center, Brooklyn, NY, ²SUNY Downstate Medical Center, Brooklyn, NY, ³SUNY Downstate Medical Center, dep. of Comparative Medicine, Brooklyn, NY, ⁴SUNY Downstate Health Sciences University, Department of Medicine, Brooklyn, NY, ⁵Columbia University Medical Center, New York, NY, ⁶Division of Rheumatology, Queen Elizabeth II Health Sciences Center (Nova Scotia Rehabilitation Site) and Dalhousie University, Halifax, NS, Canada
Background/Purpose: Neuropsychiatric (NP) involvement is common in systemic lupus erythematosus (SLE). Manifestations often include seizures and cognitive impairment but underlying etiology remains poorly understood. Brain…
Abstract Number: 1010 • ACR Convergence 2021
Proton Pump Inhibitors Suppress IL-1 Mediated Carditis in a Murine Model of Kawasaki Disease
Paul Tsoukas¹, Melissa Kleinau², Lysa Langevin², Lily Morikawa³, Trang Duong¹, Suzanne Tam⁴ and Rae Yeung⁵, ¹Hospital for Sick Children, Toronto, ON, Canada, ²University of Toronto, Toronto, ON, Canada, ³The Hospital for Sick Children, Toronto, ON, ⁴Hospital for Sick Children, Toronto, ON, ⁵The Hospital for Sick Children, Toronto, ON, Canada
Background/Purpose: Kawasaki disease (KD), is the leading cause of acquired heart disease in childhood. Up to 20% of patients may develop coronary artery lesions (CAL)…
Abstract Number: 1513 • ACR Convergence 2021
Control of T Cell Tolerance by the NR4A Family of Nuclear Receptors
Ryosuke Hiwa¹, Hailyn Nielsen¹, James Mueller¹ and Julie Zikherman², ¹University of California San Francisco, San Francisco, CA, ²UCSF Medical Center, San Francisco, CA
Background/Purpose: Current therapies for autoimmune disease often lead to treatment-limiting immunosuppression. Selective manipulation of antigen (Ag)-specific immune responses could enhance our therapeutic approach. Targeting members…
Abstract Number: 0838 • ACR Convergence 2020
T Cell–Specific CaMKIV Deficiency Protects Mice from Imiquimod-induced Glomerulonephritis
Milena Vukelic¹, Masataka Umeda¹, Andrew Ferretti², Rhea Bhargava¹, Nobuya Yoshida¹ and George Tsokos³, ¹Beth Israel Deaconess Medical Center Harvard Medical School, Boston, MA, ²Beth Israel Deaconess Medical Center Harvard Medical School, Boston, ³Division of Rheumatology & Clinical Immunology/Beth Israel Deaconess Medical Center/Harvard Medical School, Boston, MA
Background/Purpose: Systemic lupus erythematosus (SLE) is a chronic autoimmune disease characterized by autoantibody production, immune complex deposition and multisystem involvement. Calcium/calmodulin-dependent protein kinase type IV…

All abstracts accepted to ACR Convergence are under embargo once the ACR has notified presenters of their abstract’s acceptance, and cannot be presented at other meetings after this time. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. Academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part a scientific presentation or presentation of additional new information that will be available at the time of the meeting) is under embargo until November 7 at 10:00 AM ET. Journalists with access to embargoed information also cannot release articles before this time.

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Permissions and Reprints

For information about abstract permissions and reprints, see ACR Convergence permissions and reprint policies.